Trade Mark 2549733 | IP Australia

Advanced search

Number: 2549733

IR number: 1855735

Words: DYNAMICURE
Status: protected: Registered/protected
Priority date: 11 Sep 2024 (Convention)
Classes: 5, 42
Kind: Word

DYNAMICURE

Goods & Services

Class 5:: Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical preparation and substances for the treatment of genetic disorders; pharmaceutical preparations and substances for the treatment of metabolic diseases; pharmaceutical preparations and substances for the treatment of neurodegenerative diseases; pharmaceutical preparations and substances for the treatment of kidney diseases; diagnostic biomarker reagents for medical purposes; protein arrays for medical diagnosis purposes; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic preparations for medical purposes for detecting the presence of tumors, genetic disorder and autoimmune disorders and conditions; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of metabolic diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for the treatment of cardiovascular diseases; diagnostic biomarker reagents for medical purposes; protein arrays for medical diagnosis purposes; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic preparations for medical purposes; pharmaceutical preparations for the treatment of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases; all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases.

Class 42:: Research and development services in the field of biologics, namely, antibodies and peptides for the treatment of cancer and immunotherapies; research and development in the pharmaceutical and biotechnology fields for the treatment of cancer and immunotherapies; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of cancer and immunotherapies; consulting services in the fields of biotechnology, pharmaceutical research and development, and pharmacogenetics in the field of cancer and immunotherapies; conducting research for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer and immunotherapies; research and development services in the field of biologics, namely, antibodies and peptides for the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; research and development in the pharmaceutical and biotechnology fields for the treatment of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; consulting services in the fields of biotechnology, pharmaceutical research and development, and pharmacogenetics in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; conducting research for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; pharmaceutical research and development; research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; research and development in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases eye diseases, and cardiovascular diseases; providing medical and scientific research information; consulting services in the field of pharmaceutical research and development; consulting services in the field of biotechnology; consulting services in the field of pharmacogenetics; research and development in the field of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases; all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases.

Convention details

Date:

11 Sep 2024

Number:

98745375

Country:

UNITED STATES OF AMERICA

Goods & Services:

Class 05:: pharmaceutical preparations and substances for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical preparation and substances for the treatment of genetic disorders; pharmaceutical preparations and substances for the treatment of metabolic diseases; pharmaceutical preparations and substances for the treatment of neurodegenerative diseases; pharmaceutical preparations and substances for the treatment of kidney diseases; diagnostic biomarker reagents for medical purposes; protein arrays for medical diagnosis purposes; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic preparations for medical purposes for detecting the presence of tumors, genetic disorder and autoimmune disorders and conditions; All of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases

Class 42:: Research and development services in the field of biologics, namely, antibodies and peptides for the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; research and development in the pharmaceutical and biotechnology fields for the treatment of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; consulting services in the fields of biotechnology, pharmaceutical research and development, and pharmacogenetics in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; conducting research for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; All of the foregoing excluding services in the field of neuromuscular disorders and orphan diseases

Date:

08 Mar 2025

Number:

99074324

Country:

UNITED STATES OF AMERICA

Goods & Services:

Class 05:: Pharmaceutical preparations for the treatment of oncological diseases and disorders; Pharmaceutical preparations for the treatment of autoimmune diseases and disorders, autoimmune deficiency; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for the treatment of metabolic diseases; Pharmaceutical preparations for the treatment of neurodegenerative diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of eye diseases; Pharmaceutical preparations for the treatment of cardiovascular diseases; Diagnostic biomarker reagents for medical purposes; Protein arrays for medical diagnosis purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes; Pharmaceutical preparations for the treatment of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases, all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases

Class 42:: Pharmaceutical research and development; Research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; Research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; Research and development in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases eye diseases, and cardiovascular diseases; Providing medical and scientific research information; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of biotechnology; Consulting services in the field of pharmacogenetics; Research and development in the field of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases, all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases

Opposition details

No oppositions information available.

History and Publications

Date	Description
17 Oct 2025	International Registration in Australia Protected correspondence sent
16 Oct 2025	IP Right Registration Published	Trade mark details »
16 Oct 2025	Status change to Registered/Protected
09 Aug 2025	Application Accepted correspondence sent
09 Aug 2025	IP Right has been Examined
09 Aug 2025	IP Right Acceptance Published	Trade mark details »
30 May 2025	Status change to Accepted
28 May 2025	Awaiting examination
28 May 2025	Examination expedited
22 May 2025	IP Right Filed Published	Trade mark details »
22 May 2025	Status change to Published
22 May 2025	Status change to Filed
22 May 2025	Application Received
22 May 2025	IP right goods and service classes updated	More
	Event description Class Count: 2 Class Numbers:5; 42 Previous details Class Count: 0 Class Numbers: New details Class Count: 2 Class Numbers: 5; 42
22 May 2025	IP Right Goods and Services Items updated	More
	Event description Class Number: 5 Previous details New details Class Number: 5 Class Items: Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical preparation and substances for the treatment of genetic disorders; pharmaceutical preparations and substances for the treatment of metabolic diseases; pharmaceutical preparations and substances for the treatment of neurodegenerative diseases; pharmaceutical preparations and substances for the treatment of kidney diseases; diagnostic biomarker reagents for medical purposes; protein arrays for medical diagnosis purposes; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic preparations for medical purposes for detecting the presence of tumors, genetic disorder and autoimmune disorders and conditions; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of metabolic diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for the treatment of cardiovascular diseases; diagnostic biomarker reagents for medical purposes; protein arrays for medical diagnosis purposes; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic preparations for medical purposes; pharmaceutical preparations for the treatment of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases; all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases.
22 May 2025	IP Right Goods and Services Items updated	More
	Event description Class Number: 42 Previous details New details Class Number: 42 Class Items: Research and development services in the field of biologics, namely, antibodies and peptides for the treatment of cancer and immunotherapies; research and development in the pharmaceutical and biotechnology fields for the treatment of cancer and immunotherapies; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of cancer and immunotherapies; consulting services in the fields of biotechnology, pharmaceutical research and development, and pharmacogenetics in the field of cancer and immunotherapies; conducting research for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer and immunotherapies; research and development services in the field of biologics, namely, antibodies and peptides for the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; research and development in the pharmaceutical and biotechnology fields for the treatment of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; consulting services in the fields of biotechnology, pharmaceutical research and development, and pharmacogenetics in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; conducting research for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; pharmaceutical research and development; research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; research and development in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases eye diseases, and cardiovascular diseases; providing medical and scientific research information; consulting services in the field of pharmaceutical research and development; consulting services in the field of biotechnology; consulting services in the field of pharmacogenetics; research and development in the field of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases; all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases.
22 May 2025	Status change to Received
22 May 2025	Trade mark representation updated

Dates

Renewal due: 10 Mar 2035
Registration advertised / published: 16 Oct 2025
Entered on Register: 16 Oct 2025
Acceptance advertised / published: 09 Aug 2025
Acceptance: 30 May 2025
IR notification: 22 May 2025
Filing: 10 Mar 2025
Registered from: 10 Mar 2025

Owner

Address for service

IR Contact

Indexing constituents

Word